摘要
目的探讨利拉鲁肽治疗不同体重指数（BMI）2型糖尿病患者的临床效果。方法选取2型糖尿病患者100例为研究对象（均口服1种或2种降糖药物治疗后血糖控制欠佳）,按照BMI分为三组,即正常组（BMI〈24 kg/m2）32例,超重组（BMI 24～28 kg/m2）38例,肥胖组（BMI〉28 kg/m2）30例。三组患者均在原有药物治疗基础上加用利拉鲁肽治疗。3个月后,观察对比三组空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血红蛋白（Hb Alc）、体重、血脂变化及不良反应情况。结果三组治疗前FBG、2 h PG和Hb Alc指标差异均无统计学意义（P〉0.05）;治疗后除正常组FBG外,三组其余指标均低于治疗前（P〈0.05）,超重组和肥胖组改善幅度更大（P〈0.05）,且超重组和肥胖组体重较治疗前下降（P〈0.05）。三组血脂指标治疗前、后同期比较差异均无统计学意义（P〉0.05）;治疗后三组TC、TG、LDL-C均较治疗前下降（P〈0.05）,HDL-C均较治疗前升高（P〈0.05）。三组不良反应发生率比较,差异无统计学意义（P〉0.05）。结论利拉鲁肽适用于血糖控制欠佳的不同BMI 2型糖尿病患者,超重和肥胖患者临床效果更为显著。
Objective To observe and compare the effect of liraglutide in the treatment of type 2 diabetes with different body mass indexes. Methods One hundred type 2 diabetic patients taking one or two kinds of oral hypoglycemic drugs with poor glycemic control after treatment were selected and according to their body mass indexes were divided into three groups; the normal group（ n =32,BMI 24 kg / m2）; overweight group（ n = 38,BMI at 24 ～ 28 kg/m2） and obese group（ n = 30,BMI 28 kg/m2）. All the three groups were given additional liraglutide medication. 3 months later,glycated hemoglobin（ Hb Alc）,fasting blood glucose,postprandial blood glucose 2 h（ 2 h PG）,body weight and lipids and adverse reaction were compared. Results Hb Alc,2 h PG,TG,HDL-C of the3 groups before treatement had no significant difference（ P〈0. 05）; all indexes of the 3 groups,except FBG of normal group,decreased after treatment（ P〈0. 05） and overweight and obese groups improved more significantly in body weight（ P〈0. 05）; but the change of lipids showed no significant difference（ P〈0. 05）; TC,TG,LDL-C of 3 groups decreased（ P〈0. 05）; while HDL-C increased（ P〈0. 05）. There was no significant difference in the incidence rate of adverse reactions in the 3 groups（ P〈0. 05）. Conclusion Liraglutide is preferred in treatment of type 2 diabetic patients with different body mass indexes and poor control of blood glucose,especially for overweight and obese patients.
出处
《白求恩医学杂志》
2015年第2期136-138,共3页
Journal of Bethune Medical Science
